USA FACILITIES
Our Tyson Corner CLIA-certified and CAP-accredited integrated molecular diagnostics laboratory is located in suburban Washington, DC, in Maryland, close to the National Institutes of Health (NIH), one of the world's leading centers for biological research. Our proximity to and interaction with NIH, along with spirited connections with our other strategic partners in the academic, biotechnology and clinical communities enables us to stay at the forefront of diagnostic medicine and closely monitor trends and developments in molecular cytogenetics. It also allows us to take a uniquely proactive approach to the development and validation of tests in response to new and anticipated needs of research and clinical pathology. In addition to housing our cutting edge technology development programs, the laboratory offers advanced genomics-based diagnostic, prognostic and screening services for all aspects of precision medicine, ranging from genetic aberration testing, early, accurate and non-invasive cancer diagnosis and prediction of drug sensitivity or resistance to guiding personalized treatment strategies.
Services:
-- Fluorescence in situ Hybridization: full-service molecular cytogenetics testing, predominantly for oncology and prenatal medicine applications
-- Microarray and qPCR Gene Expression and mutation detection services
-- Sequencing services, including whole genome and exome analyses, comprehensive as well as targeted disease-specific panels, and a full range of next-generation sequencing (NGS) analytics solutions.
Services:
-- Fluorescence in situ Hybridization: full-service molecular cytogenetics testing, predominantly for oncology and prenatal medicine applications
-- Microarray and qPCR Gene Expression and mutation detection services
-- Sequencing services, including whole genome and exome analyses, comprehensive as well as targeted disease-specific panels, and a full range of next-generation sequencing (NGS) analytics solutions.
Email:
[email protected]
[email protected]
Telephone:
240-510-1889
Address:
1980 Gallows Rd #300, Tysons, VA 22182, USA
[email protected]
[email protected]
Telephone:
240-510-1889
Address:
1980 Gallows Rd #300, Tysons, VA 22182, USA
Dr. William G Kearns is a well-known expert in the genetics arena, particularly in the preimplantation genetics fields. After earning his doctorate at Eastern Virginia Medical School, Dr. Kearns completed his advanced training in medical genetics at the McKusick-Nathans Institute of Genetic Medicine of The Johns Hopkins University School of Medicine. He continued to serve in the role of a medical geneticist on the faculty of Johns Hopkins, where he is an associate professor. Dr. Kearns brings important experience to our diagnostic and research laboratory, including his 14 prior years in starting and directing a preimplantation genetic diagnostic company. He is a member of various professional societies and serves on the oversight committee on Reproductive Medicine and Genetics for the Department of Gynecology/Obstetrics, Genetics at The Johns Hopkins University School of Medicine and The Johns Hopkins Hospital.
Dr. Kearns’ editorial activities include being an Advisor to the British Medical Journal in Genetics, as well as Section Head of Genetics for the Journal of Assisted Reproduction and Genetics, and providing peer-review activities for Human Molecular Genetics, Genomics, Human Gene Therapy, Human Reproduction, Fertility and Sterility, RBMonline, and Molecular Human Reproduction. Dr. Kearns has served as a grant reviewer for the National Institutes of Health, the National Science Foundation, the American Heart Association and the Medical Research Council of the United Kingdom (Molecular Cytogenetics). He has applied for and received funding from numerous sources including the National Institutes of Health and the Cystic Fibrosis Foundation. Dr. Kearns has authored numerous publications and is an international lecturer in genetics.
Dr. Kearns’ editorial activities include being an Advisor to the British Medical Journal in Genetics, as well as Section Head of Genetics for the Journal of Assisted Reproduction and Genetics, and providing peer-review activities for Human Molecular Genetics, Genomics, Human Gene Therapy, Human Reproduction, Fertility and Sterility, RBMonline, and Molecular Human Reproduction. Dr. Kearns has served as a grant reviewer for the National Institutes of Health, the National Science Foundation, the American Heart Association and the Medical Research Council of the United Kingdom (Molecular Cytogenetics). He has applied for and received funding from numerous sources including the National Institutes of Health and the Cystic Fibrosis Foundation. Dr. Kearns has authored numerous publications and is an international lecturer in genetics.
Dr. Reinhard Ebner is a research manager and senior investigator with more than 30 years of scientific, technical and strategic experience, in both academic and corporate settings. Dr. Ebner has served on the faculty of the Genetics department at the University of Osnabrück, Germany, where he also had received his doctorate. He subsequently was awarded a research fellowship to work as a visiting scientific specialist at Genentech, Inc. in San Francisco, working in the fields of cytokine biology, receptor-ligand interactions and intracellular trafficking, cell differentiation, early development and tissue repair. Following similar projects at the University of California, San Francisco and at Stanford University Medical School, he moved to Human Genome Sciences in 1995, to serve as a research scientist. In 2000, he joined Avalon Pharmaceuticals, where his work was focused in chemical genomics, cancer research, data mining and HTS assay development. Dr. Ebner has been involved with the National Cancer Institute for many years, and is currently a research adviser in its cancer genomics section. He has authored nearly 100 original research publications, with several thousand citations by others, has over 50 issued US patents and is the primary inventor on more than 800 patent applications worldwide. Several of his discoveries have led to new therapeutics now in the clinic or on the market.
Mr. Joseph Cheng, MBA is the president and CEO of CytoTest. Mr. Cheng has over 20 years of combined experience in the biomedical arena, much of it acquired while working at the National Institutes of Health, as a member of the National Cancer Institute, within the Thomas Ried Laboratory team in the NIH cancer genomics section, and prior to that at the National Human Genome Research Institute, working on the Human Genome project. This background, along with an MBA from the University Of the District Of Columbia, has given Mr. Cheng a unique perspective, ideally suited for navigating the intricacies and emerging trends in the biotechnology field. Serving as the CEO of CytoTest Inc., a company focused on DNA reagents for cancer diagnostics, his products have received praise for their high quality, cost- effective production, convenient use and and broad versatility, something that he now hopes to do with gene testing.